NASDAQ · ACRS
Healthcare · Medical - Diagnostics & Research
$3.80
Down-$0.06 (-1.58%)
Updated Nov 3, 2026, 10:45 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ACRS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
ACRS closed at $3.80 after 21 trading sessions, down 11.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $4.085 | $4.085 | $3.765 | $3.80 | 1.65M |
| Oct 30, 2026 | $4.00 | $4.07 | $3.87 | $3.97 | 1.88M |
| Oct 29, 2026 | $4.01 | $4.0789 | $3.96 | $3.99 | 1.46M |
| Oct 28, 2026 | $3.70 | $3.975 | $3.66 | $3.96 | 3.88M |
| Oct 27, 2026 | $3.98 | $4.00 | $3.44 | $3.79 | 7.99M |
| Oct 26, 2026 | $3.78 | $3.85 | $3.715 | $3.79 | 1.57M |
| Oct 23, 2026 | $3.81 | $3.845 | $3.6814 | $3.75 | 2.29M |
| Oct 22, 2026 | $3.77 | $3.98 | $3.735 | $3.83 | 2.8M |
| Oct 21, 2026 | $3.74 | $3.97 | $3.69 | $3.81 | 2.66M |
| Oct 20, 2026 | $3.41 | $3.81 | $3.37 | $3.77 | 3.5M |
| Oct 19, 2026 | $3.28 | $3.50 | $3.255 | $3.48 | 1.75M |
| Oct 16, 2026 | $3.51 | $3.53 | $3.245 | $3.28 | 2.46M |
| Oct 15, 2026 | $3.42 | $3.505 | $3.34 | $3.49 | 2.59M |
| Oct 14, 2026 | $3.38 | $3.47 | $3.34 | $3.38 | 2.59M |
| Oct 13, 2026 | $3.65 | $3.652 | $3.41 | $3.47 | 3.44M |
| Oct 12, 2026 | $3.80 | $3.835 | $3.585 | $3.60 | 3.43M |
| Oct 9, 2026 | $3.76 | $3.94 | $3.64 | $3.83 | 5.06M |
| Oct 8, 2026 | $3.37 | $3.815 | $3.1818 | $3.79 | 8.74M |
| Oct 7, 2026 | $3.595 | $3.62 | $3.315 | $3.40 | 9M |
| Oct 6, 2026 | $4.22 | $4.24 | $3.65 | $3.70 | 3.53M |
| Oct 5, 2026 | $4.34 | $4.41 | $4.065 | $4.27 | 7.02M |
The latest Smart Investors Daily articles mentioning ACRS.
Company
Market Activity
Research & News
ACRS research
Company profile and research snapshot.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Canaccord Genuity | Buy | — |
| Oct 28, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 28, 2026 | Wedbush | Outperform | — |
| Sep 1, 2026 | Canaccord Genuity | Buy | — |
| Jun 2, 2026 | LifeSci Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Mar 20, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from
Benzinga · Mar 19, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
Benzinga · Mar 18, 2026
Yahoo · Feb 26, 2026
Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company’s clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer’s Annual Healthcare Conference, emphasizing programs in inflammatory and immunological diseases spanning monoclonal antibodies, a bispecific a
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACRS.
